当前位置:
X-MOL 学术
›
ACS Appl. Mater. Interfaces
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Polydopamine-Coated Radiolabeled Microspheres for Combinatorial Radioembolization and Photothermal Cancer Therapy
ACS Applied Materials & Interfaces ( IF 8.3 ) Pub Date : 2023-02-28 , DOI: 10.1021/acsami.2c19829 Manran Wu 1 , Lei Zhang 2 , Kexin Shi 1 , Dongxu Zhao 2 , Weipeng Yong 1 , Lingling Yin 1 , Ruizhe Huang 1 , Guanglin Wang 1 , Gang Huang 3 , Mingyuan Gao 1
ACS Applied Materials & Interfaces ( IF 8.3 ) Pub Date : 2023-02-28 , DOI: 10.1021/acsami.2c19829 Manran Wu 1 , Lei Zhang 2 , Kexin Shi 1 , Dongxu Zhao 2 , Weipeng Yong 1 , Lingling Yin 1 , Ruizhe Huang 1 , Guanglin Wang 1 , Gang Huang 3 , Mingyuan Gao 1
Affiliation
Transarterial radioembolization (TARE) is a local radionuclide therapy and is successfully used in hepatocellular carcinoma (HCC) treatment. Radioactive microspheres have been widely studied for TARE. Preparation of ideal radioactive microspheres is significant for clinical research and patient treatment. In this study, we have designed a novel multifunctional microsphere, i.e., polydopamine (PDA)-coated 177Lu-radiolabeled silica microspheres (MS) denoted as 177Lu-MS@PDA, which can be used for TARE and photothermal therapy (PTT). The radiostability of 177Lu-MS@PDA was significantly improved by coating 177Lu-MS with PDA. In addition, the coating of PDA makes microspheres have excellent photothermal performance. MicroSPECT/CT images showed that 177Lu-MS@PDA was accurately embolized and remained in the tumor during the observation time. At the time, it also showed that 177Lu-MS@PDA was very stable in vivo. Furthermore, the anti-tumor results demonstrated that TARE combined with PTT of 177Lu-MS@PDA can significantly inhibit tumor growth without obvious side effects. 177Lu-MS@PDA holds great potential as a promising radioactive microsphere for HCC.
中文翻译:
用于联合放射栓塞和光热癌症治疗的聚多巴胺涂层放射性标记微球
经动脉放射栓塞术 (TARE) 是一种局部放射性核素疗法,已成功用于肝细胞癌 (HCC) 的治疗。放射性微球已被广泛研究用于 TARE。制备理想的放射性微球对于临床研究和患者治疗具有重要意义。在这项研究中,我们设计了一种新型多功能微球,即聚多巴胺 (PDA) 包被的177 Lu-放射性标记二氧化硅微球 (MS),表示为177 Lu-MS@PDA,可用于 TARE 和光热疗法 (PTT) . 177 Lu-MS@PDA的辐射稳定性通过涂覆177显着提高带 PDA 的 Lu-MS。此外,PDA的包覆使得微球具有优异的光热性能。MicroSPECT/CT图像显示,177 Lu-MS@PDA在观察时间内被准确栓塞并留在肿瘤内。当时也表明177 Lu-MS@PDA 在体内非常稳定。此外,抗肿瘤结果表明,TARE联合177 Lu-MS@PDA的PTT可显着抑制肿瘤生长,且无明显副作用。177 Lu-MS@PDA 具有作为 HCC 有前途的放射性微球的巨大潜力。
更新日期:2023-02-28
中文翻译:
用于联合放射栓塞和光热癌症治疗的聚多巴胺涂层放射性标记微球
经动脉放射栓塞术 (TARE) 是一种局部放射性核素疗法,已成功用于肝细胞癌 (HCC) 的治疗。放射性微球已被广泛研究用于 TARE。制备理想的放射性微球对于临床研究和患者治疗具有重要意义。在这项研究中,我们设计了一种新型多功能微球,即聚多巴胺 (PDA) 包被的177 Lu-放射性标记二氧化硅微球 (MS),表示为177 Lu-MS@PDA,可用于 TARE 和光热疗法 (PTT) . 177 Lu-MS@PDA的辐射稳定性通过涂覆177显着提高带 PDA 的 Lu-MS。此外,PDA的包覆使得微球具有优异的光热性能。MicroSPECT/CT图像显示,177 Lu-MS@PDA在观察时间内被准确栓塞并留在肿瘤内。当时也表明177 Lu-MS@PDA 在体内非常稳定。此外,抗肿瘤结果表明,TARE联合177 Lu-MS@PDA的PTT可显着抑制肿瘤生长,且无明显副作用。177 Lu-MS@PDA 具有作为 HCC 有前途的放射性微球的巨大潜力。